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In 2016, a definite case of clinical variant Creutzfeldt-Jakob disease (vCJD) in a person heterozygous for 
methionine/valine (MV) at codon 129 of the prion 
protein gene (PRNP 129MV) was reported in the 
United Kingdom (1). Given the relatively atypical 
clinical features in this case, we considered it impor-
tant to ascertain the strain of prion agent to determine 
whether there had been strain adaption or whether 
the patient’s genetic background may have influ-
enced the disease phenotype. We conducted a study 
to determine whether we could isolate the same prion 
strain from this case of vCJD in a 129MV individual as 
was identified in previous 129 methionine homozy-
gous (129MM) genotype vCJD cases, consistent with 
the hypothesis of a causal link to bovine spongiform 
encephalopathy (BSE). 
The clinical features for this patient were con-
sistent with a diagnosis of either vCJD or sporadic 
Creutzfeldt-Jakob disease (sCJD). Results from mag-
netic resonance imaging (MRI) of the patient’s brain 
were suggestive of sCJD on diffusion-weighted imag-
ing (DWI) sequences, although the single coronal flu-
id-attenuated inversion recovery (FLAIR) sequence 
in this case was not diagnostic because of movement 
artifact. Results of cerebrospinal fluid (CSF) real-time 
quaking-induced conversion assay analysis and the 
direct detection assay for vCJD infection in the blood 
were negative. However, at autopsy, neuropatho-
logical examination revealed florid plaques, and 
biochemical analysis of prion protein (PrP) from the 
brain confirmed a type 2B profile, both characteristic 
of vCJD (1). Abnormal PrP was also detected in pe-
ripheral tissues. Recent studies in which researchers 
used protein misfolding cyclic amplification in CSF 
were positive in this case of vCJD, but not in sCJD cas-
es, including those with a heterozygous genotype (2). 
The Study 
We injected 18 RIII mice with 10% wt/vol frozen cen-
tral nervous system tissue, 0.02 mL intracerebrally 
and 0.1 mL intraperitoneally, from a 129MV patient 
with a clinical case of vCJD (1). The vCJD tissue sam-
ples were provided by the NHS National Prion Clinic, 
University College London (UCL) Hospitals (Lon-
don, UK), and MRC Prion Unit at UCL and sourced 
through the MRC Edinburgh Brain Bank (Edinburgh, 
Scotland, UK). The Brain Bank has full ethics approv-
al and consent for the use of tissue in research (East 
of Scotland Research Ethics Service, Ref 16/ES/0084) 
and works within the framework of the Human Tis-
sue (Scotland) Act 2006. We conducted inoculation, 
clinical scoring, and neuropathological and biochemi-
cal analysis of the mice as previously described (3–5). 
Animal studies were conducted according to the reg-
ulations of the UK Home Office Animals (Scientific 
Procedures) Act 1986. 
The isolate from the brain of the 129MV patient 
transmitted successfully; clinical and neuropathologi-
cal signs associated with prion disease appeared in 
the mice. We compared the mean incubation period, 
neuropathological signs, and biochemical analysis 
with archived records of UK 129MM vCJD central 
nervous system transmissions and UK BSE transmis-
sions. Methods used for inoculation, clinical scoring, 
and neuropathological and biochemical analysis of the 
mice were described in previous publications (3–5). 
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We investigated a clinical case of variant Creutzfeldt-Ja-
kob Disease in a person heterozygous for methionine/va-
line at codon 129 of the prion protein gene and identified 
the same strain properties in variant Creutzfeldt-Jakob 
disease in methionine homozygous persons and in bovine 
spongiform encephalopathy. These results indicate no ad-
aptation of the agent in a different genetic background.
No Adaptation of Prion Strain in Case of vCJD
Clinical signs with individual incubation periods 
ranging from 300 to 392 days postinfection (dpi) were 
apparent in the mice. The major clinical signs were 
a loss of body weight and body condition with eye 
winking and gait abnormalities. Toward the end of 
the clinical phase, a wet genital area could also be ob-
served. Pathologically confirmed disease developed 
in 14 of 16 mice (mean incubation period + SEM 341 
+ 6 dpi). This finding is within the range of previous 
transmission studies for UK vCJD in this mouse line 
(mean incubation 306–387 dpi) and similar to those 
for BSE (mean incubation 316–335 dpi). 
We also generated a transmissible spongiform 
encephalopathy (TSE) vacuolation profile from clini-
cally affected RIII mice and compared it with profiles 
from UK vCJD and BSE transmissions (Figure 1). We 
observed a mild-to-moderate gray matter vacuolation 
in the medulla, hypothalamus, and septum and mod-
erate vacuolation in the cochlear nucleus and dorsal 
raphe (Figure 1; Figure 2, panels A, B). 
We conducted an immunohistochemical analysis, 
which showed abnormal PrP deposition throughout 
the brain of both a granular and punctate nature (Fig-
ure 2, panels C–K). There was heavy staining in the 
brainstem, particularly the superior vestibular and 
cochlear nuclei, and lower midbrain, where the sub-
stantia nigra was often targeted. Most of the thalamic 
nuclei exhibited staining, but staining was more in-
tense in the habenular, hypothalamus, and the CA2 
region of the hippocampus (Figure 2, panels F–K). 
Punctate staining was also apparent in the mid-layer 
of the cortex throughout the brain. This pattern of 
staining was very similar to that observed in a vCJD 
and BSE transmission in the United Kingdom, with 
additional observations of granular deposition in the 
cerebellar cortex and small plaques occurring in the 
corpus callosum in 2 of the samples. 
Biochemical analysis of the MV isolate confirmed 
the presence of protease-resistant PrP (PrPres). We 
identified a similar type 2B–like pattern and glyco-
sylation profile in the RIII mice. This profile is char-
acterized by a predominance of the diglycosylated 
form of PrPres at ≈30 kDa, a monoglycosylated form 
at ≈27kDa, and an unglycosylated band at ≈19kDa 
(Appendix Figure, https://wwwnc.cdc.gov/EID/
article/26/6/19-1116-App1.pdf). The biochemical 
profile appears identical between the RIII-MV, RIII-
MM, and RIII-BSE isolates tested, although the RIII-
BSE isolate appeared to have less PrPres. 
Conclusions
This transmission study in RIII mice provides 
evidence that the prion strain isolated from this 
confirmed case of vCJD in a 129MV person is the 
same as that identified in typical 129MM vCJD and 
BSE cases. Further characterization in a range of 
mouse models is ongoing. However, transmission 
to RIII mice in previous studies has led to defini-
tive identification of several strains, vCJD and BSE 
in particular (6,7). 
PRNP codon 129 genotype has been shown to 
be a major factor influencing disease characteristics 
of Creutzfeldt-Jakob disease (8), but it has not been 
established if the same is true of vCJD, because pre-
vious vCJD infections in 129MV persons exposed 
to contaminated blood products have been asymp-
tomatic (9,10). Earlier studies using gene-targeted 
mice inoculated with vCJD predicted that codon 129 
genotype would determine disease susceptibility 
and incubation periods (11), whereas other trans-
genic mouse studies demonstrated that BSE could 
transmit with a different phenotype in mice express-
ing 129MV than that observed in mice expressing 
129MM (12). 
The clinical diagnosis in the MV case we report 
was uncertain while the patient was alive, and it was 
only at autopsy that neuropathology and biochem-
istry confirmed vCJD. The neurologic features alone 
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Figure 1. Vacuolation profiles of a clinical case of vCJD in a 
prion protein gene codon 129MV individual, pooled data from 
UK 129MM cases (n = 7) and pooled data from UK bovine 
spongiform encephalopathy cases (n = 8) show similarities in 
vacuolar pathology intensity and distribution in wild-type mouse 
brains. Data show mean ± SEM of clinical and pathological 
positive mice (n≥6 per group). G1–G9, gray matter scoring 
regions: G1, medulla; G2, cerebellum; G3, superior colliculus; 
G4, hypothalamus; G5, thalamus; G6, hippocampus; G7, septum; 
G8, retrosplenial and adjacent motor cortex; G9, cingulate and 
adjacent motor cortex. W1–W3, white matter scoring regions: 
W1, cerebellar white matter; W2, mesencephalic tegmentum; W3, 
cerebral peduncle. MM, methionine homozygous; MV, methionine/
valine; vCJD, variant Creutzfeldt-Jakob disease.
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cannot be used to discriminate between sCJD and 
vCJD, and the MRI findings on DWI imaging favored 
a diagnosis of sCJD. However, the high sensitivity 
and specificity of MRI for vCJD were determined by 
analyzing FLAIR images primarily (13) and recent re-
view suggests that DWI imaging may be less specific 
than FLAIR imaging in vCJD. It is possible that the 
phenotype of vCJD in this case may have been altered 
by the heterozygous PRNP background and investi-
gations including CSF protein misfolding cyclic am-
plification (2), tonsil biopsy, and perhaps FLAIR MRI 
may contribute to accurate diagnosis of future hetero-
zygous cases. 
The identification of vCJD in a 129MV person 
may indicate the start of a second wave of vCJD in as-
sociation with the 129MV genotype which is present 
in around 45% of the UK population (14), although no 
further cases have been reported since 2016. This case 
highlights the need to continue surveillance to iden-
tify new cases of vCJD and the need for autopsy and 
strain typing in persons with prion diseases. Changes 
in clinical disease phenotype could mask the true di-
agnosis and may be indicative of potential changes in 
prion disease strains and infectious properties. Strain 
identification and assessing the infectious proper-
ties of prion diseases are essential components in the 
management of these diseases and have important 
implications for public health and in determining the 
prevalence of BSE-related prion disease in humans. 
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Figure 2. Neuropathology of RIII 
mice inoculated with material 
from a clinical case of vCJD in a 
prion protein gene codon 129MV 
individual, a typical 129MM 
case of vCJD, and BSE. A, B) 
Haemotoxylin and Eosin staining 
of transmissible spongiform 
encephalopathy vacuolation in 
the cochlear nucleus of mice 
inoculated with material from a 
clinical 129MV case (arrows). 
C–E) Abnormal PrP deposition 
in the cerebellum of mice 
inoculated with C) clinical 129MV 
case, D) typical 129MM case, 
and E) BSE. F–H) Abnormal PrP 
deposition in the hippocampus of 
mice inoculated with samples of 
F) clinical 129MV case, G) typical 
129MM case, and H) BSE. I–K) 
Abnormal PrP deposition in the 
CA2 region of the hippocampus; 
I) inset from panel F; J) inset 
from panel G; K) inset from panel 
H. Monoclonal antibody: 6H4. 
Scale bars: A–B, F–H: 200 µm. 
C–E, I–K: 100 µm. BSE, bovine 
spongiform encephalopathy; 
MM, methionine homozygous; 
MV, methionine/valine; PrP, 
prion protein; vCJD, variant 
Creutzfeldt-Jakob disease.
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